At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
RVL-1201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)
In Brief
A Phase 3 clinical trial evaluating RVL-1201 and Vehicle ophthalmic solution for Blepharoptosis. Completed, enrolled 234 participants across 35 sites.
Detailed Summary
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharoptosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionMar 2019
Study CompletionMar 2019
TodayJul 2026
First PostedMay 25, 2018
Enrollment StartJun 20, 2018
Primary CompletionMar 14, 2019
Study CompletionMar 27, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.1 years ago
Interventions
RVL-1201drug
RVL-1201 ophthalmic solution, 0.1%
Vehicle ophthalmic solutionother
Vehicle placebo ophthalmic solution